DPP4 and Parkinson disease: While the outcomes from the clinical trials regarding the therapeutic potential of GLP-1RAs (and DPP-4 inhibitors) in AD and PD are eagerly anticipated in the near future (Table 2), some additional considerations are worth pointing out for the transition into the clinical setting.